OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase

Rhea-AI Filing Summary

OKYO Pharma Limited filed a report noting that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on Nasdaq at $1.61 per share, increasing his holding to 31,201 shares. The company also highlights urcosimod, its lead drug candidate for neuropathic corneal pain and inflammatory eye diseases, which has shown anti-inflammatory and pain-reducing activity in preclinical models. OKYO recently reported positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial in 18 neuropathic corneal pain subjects and earlier significant pain reduction in a 240-subject Phase 2 dry eye disease trial. The company plans to start an approximately 150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain in the first half of the year.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 19, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: March 19, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated March 19, 2026

4

Exhibit 99.1

 OKYO Pharma Announces Director Acquires Shares

London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Inquiries:

Business Development & Investor Relations Paul Spencer +44 (0)20 7495 2379

-1-

FAQ

What did OKYO Pharma (OKYO) disclose about its director share purchase?

OKYO Pharma reported that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on Nasdaq at $1.61 per share. Following this transaction, his total holding in the company increased to 31,201 shares, as disclosed in the March 2026 report.

What is urcosimod and what eye conditions is OKYO Pharma targeting?

Urcosimod is a lipid-conjugated chemerin peptide agonist of the ChemR23 receptor on immune and nerve cells in the eye. OKYO Pharma is developing it as an investigational therapy for neuropathic corneal pain and inflammatory eye diseases, including dry eye disease, based on preclinical and clinical data.

What clinical trial results has OKYO Pharma reported for urcosimod in neuropathic corneal pain?

OKYO Pharma recently reported positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial of urcosimod in 18 neuropathic corneal pain subjects. The trial showed pain-reducing activity, supporting further development of the drug candidate in this indication.

How has urcosimod performed in dry eye disease studies mentioned by OKYO Pharma (OKYO)?

In an earlier Phase 2 multi-center, double-masked, placebo-controlled trial involving 240 dry eye disease subjects, urcosimod showed significant pain reduction. This result supports OKYO Pharma’s rationale for developing urcosimod for neuropathic corneal pain as well as inflammatory eye conditions.

What are OKYO Pharma’s next planned clinical steps for urcosimod?

OKYO Pharma plans to initiate an approximately 150-subject Phase 2b/3 multiple-dose study of urcosimod to treat neuropathic corneal pain in the first half of the year. This larger trial is intended to further evaluate the candidate’s efficacy and safety in this indication.

What type of company is OKYO Pharma and where is it listed?

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases. Its ordinary shares are listed for trading on the Nasdaq Capital Market under the ticker symbol OKYO, as described in the disclosure.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 9.0 KB
• EX-99 GRAPHIC 19.3 KB